iBio Inc
Company Profile
Business description
iBio Inc is a clinical-stage biotechnology company using Artificial Intelligence (AI) for the development of hard-to-drug precision antibodies for obesity, cardiometabolic, and cardiopulmonary diseases. Its product candidate pipeline includes IBIO-610, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody program targeting myostatin, growth differentiation factor 11 (GDF11), and Activin A; IBIO-600; Amylin Antibody; and Target 4, in different stages of development, being developed as potential therapies for obesity and cardiometabolic disease. The company operates as one reportable segment, which is that of a biotechnology company leveraging AI and ML for the development of hard-to-drug precision antibodies.
Contact
11750 Sorrento Valley Road
Suite 200
San DiegoCA92121
USAT: +1 979 446-0027
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2027
Employees
23
iBio Inc News & Analysis
stocks
Looking under the hood at Robinhood
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,271.40 | 6.30 | 0.07% |
| CAC 40 | 8,405.42 | 4.24 | 0.05% |
| DAX 40 | 26,411.14 | 158.85 | -0.60% |
| Dow JONES (US) | 53,559.99 | 9.45 | -0.02% |
| FTSE 100 | 10,824.26 | 31.72 | 0.29% |
| HKSE | 25,566.99 | 17.80 | -0.07% |
| NASDAQ | 26,402.42 | 138.93 | -0.52% |
| Nikkei 225 | 66,311.93 | 93.63 | -0.14% |
| NZX 50 Index | 13,917.30 | 149.12 | 1.08% |
| S&P 500 | 7,711.76 | 19.23 | -0.25% |
| S&P/ASX 200 | 9,076.00 | 10.40 | 0.11% |
| SSE Composite Index | 3,986.30 | 34.12 | 0.86% |